A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in atrial fibrillation

Characteristics	MgSO₄	Placebo
No randomized (n)	41	14
Sex
Male (%)	41.46 %	0.71 %
Female	58.53 %	92 %
Age, yrs., Range	72.0 (50 – 70)	73.0 (51 – 71.0 )
History of Alcohol Abuse (%)	51.95 %	72 %
History of Antiarrhythmic Use	77%	33%
History of RHD (%)	19.51 %	28.57 %
History of CAD (%)	17.07 %	21.42 %
History of Hypothyroid (%)	9.75 %	21.42 %
Currently receiving Antiarrhythmic drugs (%)	1.07 %	21.42 %
Duration of Symptoms:
Within 24 hr (n)	41	14
After 24 hr (n)	1	14
ECG after 24 hrs – Rate (Mean)	84.51	112.2
Rhythm (%)	NSR (65%)	AF (85%)
ICU Stay (Mean)	2.25 days	4.25 days

Measurement of effect of MgSO₄ using ECG and pulse rate

	Mean	S.D	S.E	95% CI	P value
Drugs Given
Mgso4	1.8585	0.11175	0.01745	–	<0.0001
Placebo	1.8929	0.09169	0.02450
ECG rate at presentation
Mgso4	84.5122	8.54729	1.33486	–	<0.0001
Placebo	112.2857	7.89770	2.11075
ECG Rhythm At 24hrs
Mgso4	74.5	4.58	–
Placebo	25.5	3.45	–
Heart Rate
At Presentation to ED				Mean Pulse rate difference, Beats/Min (95% CI)
MgSO₄	162.7561	25.12845	3.92440	154.8246-170.6876	0.015
Placebo	177.2143	16.02008	4.28155	167.9646-186.464
After 30 minutes
MgSO₄	159.3902	23.75	3.70	-12.60 (-26.32 – 1.10)
Placebo	172.0000	15.92	4.25		0.071
After 60 minutes
MgSO₄	147.6829	19.63	3.066	-12.60 (-24.07 – -1.12)	0.032
Placebo	160.2857	14.35	3.836
After 90 minutes
MgSO₄	129.9756	14.218	2.22	-18.31 (-27.10 – -9.51)	0.001
Placebo	148.2857	13.980	3.736
After 120 minutes
MgSO₄	111.2195	8.802	1.374	-23.85 (-30.53 – -12.16)	0.001
Placebo	135.07	15.304	4.09
After 150 minutes
MgSO₄	96.1220	5.58	0.87	-27.94 (-33.29 – -13.60)	0.001
Placebo	24.07	14.34	3.83
Paired Test of Heart Rate after 30 Mins & 150 Mins
	Mean	Std dev	Std Err	95% CI	P
After 30 minutes	162.6	22.57	3.044	53.77-64.95	<0.0001
After 150 minutes	103.23	14.955	2.01

Minimum adverse effects after drug administration

		Frequency	Percent	Valid Percent	Cumulative Percent	P value
Valid	MgSO4	5	12.2	12.2	12.2	–
	Placebo	2	14.3	14.3	14.3	–
CROSS TABULATION
Drug Administration/ Adverse effects			Adverse	effects	Total
			1.00	2.00
DRUG Administration	MgSO4	Count % Within DRUG Administration	512.2%	36 87.8%	41 100.0%	0.839
		% Within DRUG adverse effects	71.4%	75%	74.5%
		% Of total	9.1%	65.5%	74.5%
	Placebo	Count	2	12	14
		% Within DRUG Administration	14.3	85.7%	100%
		% Within DRUG adverse effects	28.6%	25.0%	25.5%
		% Of total	3.6%	21.8%	25.5%
	Total	Count	7	48	55
		% Within DRUG Administration	12.7%	87.3%	100%
		% Within DRUG adverse effects	100%	100%	100%
		% Of total	12.7%	87.3%	100%

Descriptive statistics of the patient characteristics

	N	Minimum	Maximum	Sum	Mean		std
	Statistic	Statistic	Statistic	Statistic	Statistic	Std error	Statistic
Age	55	32	80	2981	54.2	1.62	12.05
Heart rate at presentation	55	124	212	9154	166.43	3.219	23.87
MgSO4	55	1.7	2.1	102.7	1.867	0.014	0.107
After 30 minutes	55	125	201	8943	162.6	3.044	22.57
After 60 minutes	55	120	185	8299	150.9	2.57	19.12
After 90 minutes	55	107	169	7405	134.6	2.18	16.17
After 120 minutes	55	99	151	6451	117.29	2.016	14.95
After 150 minutes	55	89	147	5678	103.23	2.016	14.95
ECG Rate 24Hr	55	72	127	5037	91.58	1.99	14.77
ICU stay	55	1.0	6.0	124	2.25	0.17	1.322

DOI: https://doi.org/10.2478/acm-2022-0011 | Journal eISSN: 1338-4139 (formerly 1335-8421) | Journal ISSN: 1335-8421

Language: English

Page range: 91 - 101

Submitted on: Apr 14, 2022

Accepted on: Jun 4, 2022

Published on: Aug 23, 2022

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Publication frequency: 3 issues per year

Keywords:

Related subjects:

© 2022 K Raghu, TV Ramakrishnan, G Sreedevi, P Shreevani, S Gopala Krishna, B Ravishankar, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Figures & Tables